CA
NZ
UK
AU
IND
US
TScan Therapeutics is a Nasdaq-listed, clinical-stage biotechnology company developing T-cell receptor-engineered (TCR-T) cell therapies for cancer and other diseases. On September 2, 2026, TScan announced a strategic reorganization to concentrate on in vivo-engineered TCR-T therapy for solid tumors. The plan advances two candidates targeting …
Heron Therapeutics is a Nasdaq-listed commercial-stage pharmaceutical company built around its proprietary Biochronomer drug-delivery technology. Its portfolio spans acute-care and oncology-supportive products, including ZYNRELEF and APONVIE in acute care and CINVANTI and SUSTOL in the oncology-supportive space. The pivotal recent development came on June …
Zivo Bioscience develops therapeutic and nutritional products derived from proprietary algal cultures, targeting animal health, human health and dietary-supplement markets. Its intellectual property centers on proprietary algal strains and patented production techniques. A notable structural development came in May 2026, when the company transitioned …
Atossa Therapeutics is a Nasdaq-listed, clinical-stage biopharmaceutical company focused on breast cancer. Its lead asset is (Z)-endoxifen, an oral selective estrogen receptor modulator and degrader in Phase 2 development for breast-cancer treatment and risk reduction, with exploration in additional therapeutic areas. Through 2026 the …
BNB Plus Corp. is the rebranded successor to Applied DNA Sciences, a change unveiled in late 2025 as management pivoted toward a digital-asset treasury model centred on the BNB token. Crucially, the company did not abandon its scientific roots: it retains a biopharmaceutical and …
Trinity Biotech, headquartered in Ireland and listed on Nasdaq, develops and markets medical diagnostic products spanning clinical-laboratory and point-of-care testing, including assays for infectious diseases, sexually transmitted infections and diabetes monitoring. In a striking diversification, the company has launched Trinovium, a subsidiary focused on …
Accendra Health began trading on the New York Stock Exchange under the ticker ACH on January 2, 2026, after its predecessor, Owens & Minor, sold its Products & Healthcare Services distributionBusinessand the Owens & MinorBrandon December 31, 2025. What remained, the home-based care operation …
● There is no single confirmed catalyst behind the latest quiet session, the snapshot shows the stock essentially unchanged.
● Small-cap medical-device stocks trading under a dollar frequently see outsized swings on light volume, shifts in sentiment or broader sector rotation.
● Zimmer Biomet designs, manufactures and markets reconstructive implants for knees, hips and extremities, alongside its sports medicine, extremities and trauma franchise, plus cranio-maxillofacial and surgical technologies, including its ROSA robotics platform.
Please wait processing your request...